Mary J. Kuffel

1.1k total citations
30 papers, 734 citations indexed

About

Mary J. Kuffel is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Mary J. Kuffel has authored 30 papers receiving a total of 734 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 13 papers in Genetics and 9 papers in Molecular Biology. Recurrent topics in Mary J. Kuffel's work include Estrogen and related hormone effects (12 papers), Cancer Treatment and Pharmacology (10 papers) and Pharmacogenetics and Drug Metabolism (9 papers). Mary J. Kuffel is often cited by papers focused on Estrogen and related hormone effects (12 papers), Cancer Treatment and Pharmacology (10 papers) and Pharmacogenetics and Drug Metabolism (9 papers). Mary J. Kuffel collaborates with scholars based in United States, Austria and Australia. Mary J. Kuffel's co-authors include Matthew M. Ames, Joel M. Reid, J.K. Miller, Rafael Ríos, Matthew P. Goetz, Vera J. Suman, Stephanie L. Safgren, Sarah A. Buhrow, James N. Ingle and Jennifer C. Schroeder and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Mary J. Kuffel

28 papers receiving 714 citations

Peers

Countries citing papers authored by Mary J. Kuffel

Since Specialization

Citations

This map shows the geographic impact of Mary J. Kuffel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary J. Kuffel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary J. Kuffel more than expected).

Fields of papers citing papers by Mary J. Kuffel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary J. Kuffel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary J. Kuffel. The network helps show where Mary J. Kuffel may publish in the future.

Co-authorship network of co-authors of Mary J. Kuffel

This figure shows the co-authorship network connecting the top 25 collaborators of Mary J. Kuffel. A scholar is included among the top collaborators of Mary J. Kuffel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary J. Kuffel. Mary J. Kuffel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract P4-12-23: Z-Endoxifen-PROTAC, a novel drug for chemo-sensitive and-resistant Triple Negative Breast Cancer 2025 ·Clinical Cancer Research ·(unknown), Sayantani Sarkar Bhattacharya, Thomas R. Caulfield, Stephanie L. Safgren, Sarah A. Buhrow, Joel M. Reid, Mary J. Kuffel, (unknown), Akhilesh Pandey, (unknown), Matthew M. Ames, John R. Hawse, Matthew J. Schellenberg, Matthew P. Goetz	0
2	Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer 2023 ·npj Breast Cancer ·(unknown), Xinyan Wu, Krishna R. Kalari, Xiaojia Tang, Mary J. Kuffel, Elizabeth S. Bruinsma, Shahrzad Jalali, Kevin L. Peterson, Cristina Correia, Rachel A. Kudgus, Scott H. Kaufmann, Santosh Renuse, James N. Ingle, Joel M. Reid, Matthew M. Ames, Alan P. Fields, Matthew J. Schellenberg, John R. Hawse, Akhilesh Pandey, Matthew P. Goetz	4
3	Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies 2014 ·Cancer Chemotherapy and Pharmacology ·Joel M. Reid, Matthew P. Goetz, Sarah A. Buhrow, Chad A. Walden, Stephanie L. Safgren, Mary J. Kuffel, Kathryn E. Reinicke, Vera J. Suman, Paul Haluska, Xiaonan Hou, Matthew M. Ames	34
4	Abstract PD3-4: A first-in-human phase I study of the tamoxifen (TAM) metabolite, Z-endoxifen hydrochloride (Z-Endx) in women with aromatase inhibitor (AI) refractory metastatic breast cancer (MBC) (NCT01327781) 2013 ·Cancer Research ·(unknown), (unknown), (unknown), (unknown), (unknown), Travis Dockter, (unknown), Mary J. Kuffel, (unknown), Stephanie L. Safgren, Renee M. McGovern, (unknown), Howard Streicher, (unknown), Charles Erlichman, JN Ingle, (unknown)	5
5	Methylenedioxy- and Ethylenedioxy-Fused Indolocarbazoles: Potent Human Topoisomerase I Inhibitors and Antitumor Agents 2012 ·Anti-Cancer Agents in Medicinal Chemistry ·David E. Zembower, (unknown), (unknown), Mary J. Kuffel, Matthew M. Ames, Yasheen Zhou, Rama K. Mishra, (unknown), Michael T. Flavin, (unknown)	8
6	Abstract PD10-08: Venlafaxine inhibits the CYP2D6 mediated metabolic activation of tamoxifen: Results of a prospective multicenter study: (NCT00667121) 2012 ·Cancer Research ·(unknown), Vera J. Suman, N. Lynn Henry, (unknown), Stephanie L. Safgren, Markus Kosel, Mary J. Kuffel, Kostandinos Sideras, (unknown), Vered Stearns, Neelima Denduluri, (unknown), (unknown)	1
7	CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8 2012 ·Clinical Cancer Research ·Matthew P. Goetz, Vera J. Suman, Tanya L. Hoskin, Michael Gnant, Martin Filipits, Stephanie L. Safgren, Mary J. Kuffel, R. Jakesz, Margaretha Rudas, Richard Greil, Otto Dietze, Alois Lang, Felix Offner, Carol Reynolds, Richard M. Weinshilboum, Matthew M. Ames, James N. Ingle	87
8	Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats 2010 ·Cancer Chemotherapy and Pharmacology ·Joel M. Reid, Sarah A. Buhrow, Mary J. Kuffel, Lee Jia, Victoria J. Spanswick, John A. Hartley, David E. Thurston, Joseph E. Tomaszewski, Matthew M. Ames	10
9	Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells 2009 ·Cancer Chemotherapy and Pharmacology ·Kathryn E. Reinicke, Mary J. Kuffel, Matthew P. Goetz, Matthew M. Ames	13
10	Tamoxifen, HER2, and Endoxifen: The Role of CYP2D6 as a Predictor of Tamoxifen Resistance in ER+/HER2+ Breast Cancer. 2009 ·Cancer Research ·Matthew P. Goetz, Kathryn E. Reinicke, Joel M. Reid, Vera J. Suman, Mary J. Kuffel, Stephanie L. Safgren, Sarah A. Buhrow, Christopher A. Reynolds, Robert B. Jenkins, John R. Hawse, Evelyn Perez, JN Ingle, Matthew M. Ames	1
11	Preclinical Pharmacology and Toxicology of Intravenous MV-NIS, an Oncolytic Measles Virus Administered With or Without Cyclophosphamide 2007 ·Clinical Pharmacology & Therapeutics ·Rae Myers, Suzanne Greiner, (unknown), Guy E. Griesmann, Mary J. Kuffel, Sarah A. Buhrow, Joel M. Reid, Mark J. Federspiel, Matthew M. Ames, David Dingli, Karen Schweikart, Anthony Welch, Angela Dispenzieri, K-W Peng, Stephen J. Russell	105
12	Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: A North Central Cancer Treatment Group trial 2005 ·Investigational New Drugs ·Evanthia Galanis, Jan C. Buckner, Matthew J. Maurer, Joel M. Reid, Mary J. Kuffel, Matthew M. Ames, Bernd W. Scheithauer, Julie E. Hammack, (unknown), Steven A. Kuross	16
13	Kynurenine: a biomarker for in vitro and in vivo modulation of indoleamine 2,3-dioxygenase by 1-Methyl-[D]-tryptophan (NSC 721782) 2005 ·Mary J. Kuffel, Sarah A. Buhrow, Joel M. Reid, Lee Jia, Matthew M. Ames	2
14	Activation of the Antitumor Agent Aminoflavone (NSC 686288) Is Mediated by Induction of Tumor Cell Cytochrome P450 1A1/1A2 2002 ·Molecular Pharmacology ·Mary J. Kuffel, Jennifer C. Schroeder, (unknown), Stephen Naylor, Joel M. Reid, Scott H. Kaufmann, Matthew M. Ames	55
15	Indolocarbazole poisons of human topoisomerase I: Regioisomeric analogues of ED-110 1999 ·Bioorganic & Medicinal Chemistry Letters ·David E. Zembower, Heping Zhang, Jayana P. Lineswala, Mary J. Kuffel, (unknown), Matthew M. Ames	26
16	Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. 1999 ·PubMed ·Joel M. Reid, Mary J. Kuffel, J.K. Miller, Rafael Ríos, Matthew M. Ames	105
17	Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 cells 1995 ·Cancer Chemotherapy and Pharmacology ·Mary J. Kuffel, Matthew M. Ames	22
18	Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture 1992 ·Cancer Chemotherapy and Pharmacology ·Mary J. Kuffel, Joel M. Reid, Matthew M. Ames	95
19	Murine pharmacokinetics and metabolism of penclomedine [3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine, NSC 338720]. 1992 ·PubMed ·Joel M. Reid, Dane A. Mathiesen, Linda M. Benson, Mary J. Kuffel, Matthew M. Ames	13
20	Preclinical pharmacology of the anthrapyrazole analog oxantrazole (NSC-349174, Piroxantrone) 1989 ·Cancer Chemotherapy and Pharmacology ·Sandra Frank, Dane A. Mathiesen, (unknown), Mary J. Kuffel, Matthew M. Ames	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact